Skip to main content

Table 3 Sensitivity, specificity, PPV and NPV of serum S100B and PET-CT for patients with stage I or II

From: Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma

Pts with stage I or II
(68)
  PPV %
(N)
NPV%
(N)
Sensitivity% (N) Specificity% (N)
S100B 80.0% (28/35) 21.2% (7/33) 51.8% (28/54) 50.0% (7/14)
PET-CT 98.2% (54/55) 100.0% (13/13) 100.0% (54/54) 92.8% (13/14)
With clin. sign
(48)
  PPV%
(N)
NPV%
(N)
Sensitivity% (N) Specificity% (N)
S100B 93.3 (14/15) 21.3 (7/33) 65.0 (26/40) 87.5 (7/8)
PET-CT 97.5 (40/41) 100.0 (7/7) 100.0 (40/40) 87.5 (7/8)
Asymptomatic pts
(20)
  PPV%
(N)
NPV%
(N)
Sensitivity% (N) Specificity% (N)
S100B 70.0 (14/20) 0 bias 100.0 (14/14) 0 bias
PET-CT 100.0 (14/14) 100.0 (6/6) 100.0 (14/14) 100.0 (6/6)